Bio-AMD Inc. (fka BIAD)

[joenatural]

LOL, as I think you better read the 10-K again. Results 15 months ago ? LOL. That's when the development agreement was first signed and it lasts 27 months. On to phase 2 now .......

"whats to love? deal with sysmex ended 3.17.16 plus sysmex has had the results for 15 months..sounds bad to me..jmo"

[joenatural]

If I didn't know what I owned, I would sell too, except I know what I own ......

"I may sell here"

[firsttrade]

yesterday I posted facts from 10k..sysmex deal ended 3.17.16..results were given to sysmex before dec 2015..I see my post was deleted..now im really scared...I may sell here..glta

[BiotechValues]

"...the results presented to Sysmex which is now clarifying the plan for the next phase of development."

interesting....

[$TRIG$]

Say it ain't so. An AH trade on the same day we have news....

[firsttrade]

whats to love? deal with sysmex ended 3.17.16 plus sysmex has had the results for 15 months..sounds bad to me..jmo

[PatrickBateman]

Thanks for the update

[jaytea]

Somebody's lovin' that 10-K!
BIAD rockin'!

[BlockTrade]

The Study has been successfully completed and the results presented to Sysmex which is now clarifying the plan for the next phase of development. There can be no assurance that Sysmex will enter into additional agreements to jointly develop with us the Products or that such a manufacturing/license agreement will ever be consummated or that the Products will ever be commercially sold by Sysmex.
http://ih.advfn.com/p.php?pid=nmona&article=70935107

[thought013]

Almost!

[PatrickBateman]

Are we millionaires yet?

[carp1]

Nah... Going to Mars... LMAO

[jaytea]

To Da Moon!

[carp1]

$BIAD moving nicely on low volume!!

[croptop]

Yea, its an embarresment as far as I call it. China , Really? LOL,
Why even spend the money to attempt a patent there? Are people that gullible?
Get patents in countries that would and can be held accountable..
Well, guess thats not true here either..

[choctaw]

A couple weeks ago I sent the co. an email ref. China involvement. Have yet to get any response. glta

[derkampfer]

Your message is useless.


IMO

[croptop]

2 news in almost a couple yrs and both china crap....LOL
China can counterfeit any patent they want...
its useless IMO

[Bob Stocks]

Exactly

[carp1]

It's good to see shareholders showing up on the board again staying positive!! Yes the share price has deprecated greatly without significant news to give us a boost, but I will keep in check while I'm waiting and adding shares...

We must remember the company has stated in this past PR they have to remain tight lipped! http://ih.advfn.com/p.php?pid=nmona&article=69957599

The Company understands shareholder frustration with a lack of regular and detailed news about our technologies. This is largely due to confidentiality obligations and restrictions imposed on med-tech companies by larger partners.

The Company is, however, delighted with its progress and accepts these temporary restrictions as commercial reality. It is committed to updating shareholders as far as it can. It looks forward to announcing developments as restrictions are lifted.

[maxinkuckee]

Yes, the Sysmex agreement allows for a 27 month study which would expire March 17, 2017

[derkampfer]

To be clear, the deal with Sysmex was a two year deal (see SA article by Edward Vranic) and initial $1M payment. If memory serves they announced in Dec 2014 so should still be very much engaged.

Additional payments could be expected as they reach various Milestones. This and other patent announcements increase likelihood of reaching such Milestones.

Would be nice to hear something from management regarding status.

GLTA

DK

[derkampfer]

"Company is diluting"?

Baseless nonsense.

With BIADs recent patent announcement (with others on the way as they state) it better positions itself to be considered as a legitimate long term partner with someone like a Sysmex who can catapult their technology to commercialization.

Sysmex themselves would be foolish not latching-on further to these technologies BIAD is offering.

This price action means nothing of dilution. Simply impatient shareholders wanting out. Same EXACT pattern last Winter where it stayed in the $.04-.06 range for a few months.

This is an opportunity to buy, based on incredibly low market cap, patented technologies and excellent prospects with a partner.

Call it for what it is.

GLTA

DK

[carp1]

But a 45,000 form t would be equal to $2,500.00 IMO I doubt that is dilution.... Was there any other form t's during the week? TIA

[$TRIG$]

The after hours t trades. Classic signal with pennies. Plus, who whacks the bid with a 20-30% spread? Especially given the volume up tick. Just my opinion. Still a long but was making an observation.

[PatrickBateman]

Based off what?

[Bob Stocks]

Why you say that?

[$TRIG$]

Company is diluting.

[PatrickBateman]

Once commercialization news comes out this will hit $1 in a flash

[BlockTrade]

It looks as though the market wasn't impressed with today's PR Lol. I cant blame them as patents don't generate income,but see it as a step in the right direction......a lot of shares purchased at .05 & under the past two weeks will have to be burned through I'm happy with the shares recently purchased

[carp1]

Chart was set up nicely before the news today.... I think you and I are happy we added before the pop here!!! Hoping for continuation of the share price north

[BlockTrade]

I would expect .08 to .010 to be a base support again until we receive something substantial from the company.......then its off to the races.

[$Pistol Pete$]

$BIAD Bio-AMD, Inc.: MIDS Patent Grant in People's Republic of China

Source: InvestorsHub NewsWire





DARESBURY, UNITED KINGDOM--(NewMediaWireBio-AMD, Inc.: MIDS Patent Grant in People's Republic of China - Mar 3, 2016) - Bio-AMD, Inc. and Bio-AMD Holdings Ltd., our majority owned medical devices subsidiary (together "Bio-AMD," "We" or the "Company") (OTCQB: BIAD) is pleased to confirm that it has received a Certificate of Grant of a patent in the People's Republic of China ("PRC") for our Magnetic Immunoassay Detection System (MIDS) technology platform.

Patent Number ZL201180025701.5 was granted by the State Intellectual Property Office of the PRC, covering our MIDS "Immunoassay Apparatus Incorporating Microfluidic Channel."

The Company is delighted to have obtained this first territorial protection for its MIDS technology platform. The Company expects to receive further MIDS patent grants, having concurrently applied for protection in a global package of similar applications; in the U.S.A., the European Union and India. The Company believes that the PRC patent grant is indicative of the likelihood of grant in other territories, the PRC grant merely being "first past the post."

MIDS is an early stage technology platform capable of performing a wide range of immunoassay tests with significant potential for the Point of Care sector, expected to offer quantitative results and gold standard, "laboratory accuracy," at the patient's bedside, over a wide range of tests. Subject to resources being available, the Company intends to start work on the production of a MIDS technology bench demonstrator this year.

About Bio-AMD, Inc.

Bio-AMD has two majority owned UK subsidiaries: Bio-AMD Limited, a technology developer for medical diagnostic devices; and WOCU Ltd, the owner of the WOCU®, a global currency data reference source for application in financial markets (www.wocu.com).

To find out more about Bio-AMD (OTCQB: BIAD), visit our website at www.bioamd.com.

Forward-Looking Statements

Statements in this news release that are not statements of historical fact are forward-looking statements, which are subject to certain risks and uncertainties. Forward-looking statements can often be identified by words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Actual results may differ materially from those expressed or implied by forward-looking statements due to a variety of factors that may or may not be foreseeable or within the reasonable control of the Company. Readers are cautioned not to place undue reliance on such forward-looking statements. Additional information on risks and other factors that may affect the business and financial results of the Company can be found in filings of the Company with the U.S. Securities and Exchange Commission, including without limitation the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2014 filed on March 30, 2015, and in Company reports filed subsequently thereto. Except as otherwise required by law, the Company disclaims any obligations or undertaking to publicly release any updates or revisions to any forward-looking statement contained in this news release to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.




CONTACT INFORMATION



CONTACT:
Bio-AMD, Inc.
Tom Barr
CEO
[phone]

[JJSeabrook]

Bio-AMD, Inc.: MIDS Patent Grant in People's Republic of China






DARESBURY, UNITED KINGDOM--(Marketwired - Mar 3, 2016) - Bio-AMD, Inc. and Bio-AMD Holdings Ltd., our majority owned medical devices subsidiary (together "Bio-AMD," "We" or the "Company") (OTCQB: BIAD) is pleased to confirm that it has received a Certificate of Grant of a patent in the People's Republic of China ("PRC") for our Magnetic Immunoassay Detection System (MIDS) technology platform.

Patent Number ZL201180025701.5 was granted by the State Intellectual Property Office of the PRC, covering our MIDS "Immunoassay Apparatus Incorporating Microfluidic Channel."

The Company is delighted to have obtained this first territorial protection for its MIDS technology platform. The Company expects to receive further MIDS patent grants, having concurrently applied for protection in a global package of similar applications; in the U.S.A., the European Union and India. The Company believes that the PRC patent grant is indicative of the likelihood of grant in other territories, the PRC grant merely being "first past the post."

MIDS is an early stage technology platform capable of performing a wide range of immunoassay tests with significant potential for the Point of Care sector, expected to offer quantitative results and gold standard, "laboratory accuracy," at the patient's bedside, over a wide range of tests. Subject to resources being available, the Company intends to start work on the production of a MIDS technology bench demonstrator this year.

About Bio-AMD, Inc.

Bio-AMD has two majority owned UK subsidiaries: Bio-AMD Limited, a technology developer for medical diagnostic devices; and WOCU Ltd, the owner of the WOCU®, a global currency data reference source for application in financial markets (www.wocu.com).

To find out more about Bio-AMD (OTCQB: BIAD), visit our website at www.bioamd.com.

Forward-Looking Statements

Statements in this news release that are not statements of historical fact are forward-looking statements, which are subject to certain risks and uncertainties. Forward-looking statements can often be identified by words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Actual results may differ materially from those expressed or implied by forward-looking statements due to a variety of factors that may or may not be foreseeable or within the reasonable control of the Company. Readers are cautioned not to place undue reliance on such forward-looking statements. Additional information on risks and other factors that may affect the business and financial results of the Company can be found in filings of the Company with the U.S. Securities and Exchange Commission, including without limitation the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2014 filed on March 30, 2015, and in Company reports filed subsequently thereto. Except as otherwise required by law, the Company disclaims any obligations or undertaking to publicly release any updates or revisions to any forward-looking statement contained in this news release to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.







Contact Information



CONTACT:
Bio-AMD, Inc.
Tom Barr
CEO
[phone]

[carp1]

Boy my account is looking healthy today!!!

[jaytea]

And from there it's just a quick hop to .14

[jaytea]

looks like we're heading back to that .10 level.

[BlockTrade]

Weekly Chart : BIAD

[PatrickBateman]

How long is the company silenced for?

[jaytea]

somebody spent six bucks to get in on this moonshot!

[BlockTrade]

Not me,Ive added over the past two weeks.......still a great buy at the current level Imo.

[buckiii2]

Someone buying today?

[BlockTrade]

That investment in BIAD should do well for you

[Bob Stocks]

Added

[BlockTrade]

Some good background information on sysmex's partnership with Bio-AMD......
https://s3.amazonaws.com/assets.hvst.com/uploads/attachment/file/2454/Report_BIAD_4.pdf

[BlockTrade]

Patented technology currently in commercial development with a global haematology partner. BIAD currently trading @ 0.05 let's get real here! this is a steal at this level.......
http://www.bioamd.com/technology/blood-coagulation-monitor

[BlockTrade]

Monthly Chart: BIAD

[BlockTrade]

Also noted several 100k block buys the past few days GLTA

[BlockTrade]

I think it's more then one position being liquidated here...largest volume day in over a year. would expect something tangible from management at this point given the current depressed price per share.

[Bob Stocks]

I will be buying tomorrow.....and i'm thinking that a dollar is an easy target if this works out.